Login to Your Account

Deals And M&A NEWS
SHANGHAI – Making a strong move to enter China's cardiovascular (CDV) market, Shanghai-based Eddingpharm Co. Ltd. inked a deal with Amarin Corp. plc, of Dublin, to bring Vascepa to Greater China.
Blueprint Medicines Corp. will bank $15 million as an up-front payment from Cheshire, Conn.-based Alexion Pharmaceuticals Inc. as a kick-off to their strategic collaboration that will center on an undisclosed activated kinase target, which is the cause of a rare genetic disease.
Orca Pharmaceuticals Ltd. and Astrazeneca plc are joining a growing list of alliances seeking to leverage retinoic acid-related orphan nuclear receptor gamma (RORγ) inhibitors to address a wide range of autoimmune diseases.
More Deals And M&A Headlines

Cast Your Vote

Has biotech’s bubble burst?: